MediWound (NSDQ:MDWD) today announced a $25.2 million offering to support research and development of its EscharEx topical biological drug for debridement of chronic and other hard-to-heal wounds.
In the offering, the Israel-based company floated approximately 5 million shares, including 637,664 shares through an underwriter’s option, according to an SEC filing.
Cowen & Company and Wells Fargo acted as joint book-running managers for the offering, with Oppenheimer & Co and SunTrust Robinson Humphrey as co-lead managers and Aegis Capital as co-manager.
In January, MediWound touted data from a phase II trial of its EscharEx drug, which included a follow-up period of 6 months from the last treatment to 3 months from wound closure.
